Nevertheless, another randomized trial found that empagliflozin after three months of treatment in patients with T2DM increased total cholesterol, LDL-cholesterol, LDL phospholipids, LDL apolipoprotein B and free fatty acids, but had no effect on LDL particles size. Here, APOB is linked to type 2 diabetes mellitus.